Literature DB >> 7919965

HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2).

C Scheibenbogen1, U Keilholz, J Mytilineos, S Suciu, M Manasterski, W Hunstein.   

Abstract

MHC-restricted recognition of melanoma cells by cytotoxic T lymphocytes is an important mechanism in vitro. Several HLA alleles can function as restriction elements for melanoma cell recognition. In this study we investigated whether there is a correlation between responsiveness of patients with metastatic melanoma (MM) to immunotherapy and the HLA type of the patient. Seventy-two patients received immunotherapy with IFN-alpha and IL-2 according to two different schedules with an overall response rate of 24%. In 54 patients, including 16 responders and 16 patients with stable disease, in whom peripheral blood lymphocytes were available, we determined HLA haplotypes. As a control group we prospectively determined HLA types in 67 melanoma patients of all stages who underwent surgery or received chemotherapy and of 126 healthy donors from our blood bank. Two HLA alleles that have been shown to function as restriction elements in vitro were observed more frequently in responding patients, namely Cw7 (p = 0.014) and A1 (p = 0.19). No association was found for A2 and B44. These observations provide evidence that the responsiveness of MM to immunotherapy with IL-2 is associated with certain HLA types, suggesting an important role of HLA-restricted T lymphocytes for IL-2-induced tumour regression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919965     DOI: 10.1097/00008390-199406000-00008

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  8 in total

1.  Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.

Authors:  Ahmad A Tarhini; Donghoon Shin; Sandra J Lee; Joseph Stuckert; Cindy A Sander; John M Kirkwood
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

Review 2.  Immunologic functions as prognostic indicators in melanoma.

Authors:  Marna G Bouwhuis; Timo L M ten Hagen; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

Review 3.  The past, present and future of immunotherapy against tumor.

Authors:  Tao Jiang; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2015-06

4.  Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

Authors:  Jedd D Wolchok; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Dirk Schadendorf; Veerle de Pril; Kevin Heller; Tai-Tsang Chen; Ramy Ibrahim; Axel Hoos; Steven J O'Day
Journal:  Cancer Immun       Date:  2010-10-20

5.  Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

Authors:  C Bain; Y Merrouche; I Puisieux; J Y Blay; S Negrier; V Bonadona; C Lasset; F Lanier; A Duc; L Gebuhrer; T Philip; M C Favrot
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.

Authors:  Helen Gogas; John M Kirkwood; Christine S Falk; Urania Dafni; Vernon K Sondak; Dimosthenis Tsoutsos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Pectasides; Maria Spyropoulou-Vlachou
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

7.  HLA associations in the antitumor response against malignant melanoma.

Authors:  F M Marincola; P Shamamian; L Rivoltini; M Salgaller; J Cormier; N P Restifo; T B Simonis; D Venzon; D E White; D R Parkinson
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-11

Review 8.  Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.

Authors:  Nicholas L Bayless; Jeffrey A Bluestone; Samantha Bucktrout; Lisa H Butterfield; Elizabeth M Jaffee; Christian A Koch; Bart O Roep; Arlene H Sharpe; William J Murphy; Alexandra-Chloé Villani; Theresa L Walunas
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 12.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.